ISR Articles
-
Insights Into The Competitive Clinical Manufacturing Market
There are perhaps too many options when it comes to choosing the right service provider for clinical manufacturing. Drug innovators weigh in on their selection metrics and preferences as well as reveal why vendors lose bids.
-
Letting Motivations Guide The Outsourcing Approach
Outsourcing motivations are important considerations to identify the best outsourcing approach and should influence the type of relationships your organization develops with CMOs.
-
Revealing Response To A Hypothetical Question About Outsourcing Services
If you were in charge of establishing a bioprocessing contract manufacturing business, which service provider attributes would you implement to ensure your company’s success? Here's how peers in the industry responded.
-
Is OSD Becoming More Complicated?
Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Gain insight into data from ISR’s new report to provide answers to these questions and more.
-
Small & Emerging Outsourced Manufacturing Activities
To better understand the outsourcing practices used by respondents’ companies, ISR asked research participants to provide an estimate for various manufacturing activities.
-
Use Of Preferred Providers Among Biologic Outsourcers
ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list for outsourced manufacturing. The majority of respondents do, for both large molecule API (59%) and large molecule drug product manufacturing (61%).
-
Small And Emerging Biopharma Companies Outsourcing Practices
There is no question that the drug development services industry is complex, dynamic, and continuously evolving. While every sponsor company is different, all can benefit from keeping a pulse on current outsourcing practices and the activities being outsourced. Over the past year, ISR conducted several research activities with the aim of better understanding the needs of small and emerging biopharma companies and how they differ from the larger industry players. This article highlights the results of this survey.
-
How To Improve Outsourcing Relationships
ISR's Development and Commercial Outsourcing Models report indicates that proactive communication between sponsors and CMOs in these three areas will help to improve outsourcing relationships.
-
Improving Manufacturing Outsourcing Relationships
In Q4, 2018, ISR asked 100 sponsors who outsource manufacturing about several different scenarios that could potentially improve outsourcing relationships. The data below show how each of the scenarios panned out. A key common element across the most likely scenarios—communication.
-
Are Preferred Provider Agreements The Best Model For Outsourcing?
ISR has observed use of preferred provider agreements (PPAs) and the proportion of outsourcing allocated to preferred providers increase over the past three years.